微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 64.5% | -0.39% | -1.03% | 39/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 65.17% | -0.24% | -5.89% | 38/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 69.24% | 3.94% | 10.1% | 35/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 62.89% | 0.14% | -2.88% | 42/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 64.75% | -14.3% | -0.87% | 41/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 65.33% | -15.99% | -1.94% | 39/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 66.62% | -13.95% | 6.08% | 34/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 62.8% | -17.68% | -16.89% | 45/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2023-09-30 | 75.56% | -2.83% | -2.83% | 29/159 | 32.31% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-06-30 | 77.76% | -0.69% | 0.45% | 26/159 | 38.22% | 百利天恒 | 97.99% | 行业排名> |
| 2023-03-31 | 77.41% | -3.37% | 1.48% | 26/159 | 52.66% | 百利天恒 | 98.92% | 行业排名> |
| 2022-12-31 | 76.29% | 22.87% | -1.9% | 30/159 | 53.51% | 迈威生物 | 98.93% | 行业排名> |
| 2022-09-30 | 77.76% | 17.93% | -0.69% | 27/159 | 5.67% | 迈威生物 | 99.59% | 行业排名> |
| 2022-06-30 | 78.3% | 18.48% | -2.26% | 27/159 | 20.91% | 迈威生物 | 99.8% | 行业排名> |
| 2022-03-31 | 80.11% | 30.77% | 29.03% | 22/159 | 54.06% | 迈威生物 | 99.46% | 行业排名> |
| 2021-12-31 | 62.09% | -2.58% | -5.85% | 61/159 | 54.9% | 迈威生物 | 99.75% | 行业排名> |
| 2021-09-30 | 65.94% | -0.81% | -0.22% | 41/159 | 46.49% | 迈威生物 | 99.67% | 行业排名> |
| 2021-06-30 | 66.09% | 10.87% | 7.88% | 45/159 | 46.97% | 迈威生物 | 99.44% | 行业排名> |
| 2021-03-31 | 61.26% | 2.51% | -3.88% | 47/159 | 53.79% | 迈威生物 | 98.57% | 行业排名> |
| 2020-12-31 | 63.73% | 6.15% | -4.14% | 51/159 | -147.51% | 首药控股 | 99.93% | 行业排名> |
| 2020-09-30 | 66.48% | 1.83% | 11.53% | 35/159 | 56.06% | 艾力斯 | 99.41% | 行业排名> |
| 2020-06-30 | 59.61% | -8.62% | -0.25% | 52/159 | 53.85% | 艾力斯 | 98.7% | 行业排名> |
| 2020-03-31 | 59.76% | -3.12% | -0.47% | 47/159 | 54.83% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 60.04% | -20.64% | -8.04% | 59/159 | -1232.76% | 首药控股 | 99.94% | 行业排名> |
| 2019-09-30 | 65.29% | -11.21% | 0.08% | 32/159 | 54.86% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-06-30 | 65.24% | -11.71% | 5.76% | 37/159 | 54.88% | 微芯生物 | 95.14% | 行业排名> |
| 2019-03-31 | 61.68% | -12.41% | -18.47% | 38/159 | 50.75% | 多瑞医药 | 95.59% | 行业排名> |
| 2018-12-31 | 75.66% | -3.77% | 2.9% | 25/159 | -210.26% | 微芯生物 | 95.81% | 行业排名> |
| 2018-09-30 | 73.53% | -2.03% | -0.49% | 18/159 | 53.75% | 微芯生物 | 96.09% | 行业排名> |
| 2018-06-30 | 73.89% | -1.84% | 4.92% | 16/159 | 53.16% | 微芯生物 | 96.11% | 行业排名> |
| 2018-03-31 | 70.42% | -6.5% | -10.43% | 19/159 | 53.78% | 微芯生物 | 95.5% | 行业排名> |
| 2017-12-31 | 78.62% | -0.25% | 4.75% | 19/159 | 52.25% | 微芯生物 | 96.27% | 行业排名> |
| 2017-09-30 | 75.05% | -1.02% | -0.29% | 13/159 | 48.76% | 贝达药业 | 95.47% | 行业排名> |
| 2017-06-30 | 75.27% | -1.89% | -0.07% | 11/159 | 47.61% | 贝达药业 | 95.51% | 行业排名> |
| 2017-03-31 | 75.32% | -0.49% | -4.44% | 10/159 | 46.62% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 78.82% | -2.87% | 3.95% | 11/159 | 48.17% | 贝达药业 | 95.74% | 行业排名> |
| 2016-09-30 | 75.82% | -5.83% | -1.17% | 8/159 | 45.83% | 退市金泰 | 96.19% | 行业排名> |
| 2016-06-30 | 76.72% | -4.84% | 1.36% | 8/159 | 45.93% | 贝达药业 | 95.81% | 行业排名> |
| 2016-03-31 | 75.69% | -4.72% | -6.73% | 8/159 | 43.86% | 退市金泰 | 95.93% | 行业排名> |